Inhibikase presents Phase 1/1b data at AD/PD 2022; no numerical results in 8-K

Inhibikase Therapeutics, Inc.

Company presented Phase 1 and 1b clinical study results at AD/PD Conference in Barcelona on March 18, 2022.
Presentation focuses on Abl-kinase inhibition (IKT-148009) for Parkinson's disease modification.
No specific quantitative outcomes, milestones, or financial impact disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.